The first federal ban on a synthetic color due to the outdated Delaney Clause has inked a line in the sand — and crossing it could push the industry past the threshold of science-driven formulation into an era ruled by consumer perception based on misinformation.
While colors are up for interpretation, science generally is not. Health misinformation has always existed, but took centerstage during the pandemic when social media quickly became a powerful tool for disseminating false narratives and blurry science.
Speed-to-market, efficiency, flexibility, quality. These aren’t just buzzwords — they’re critical goals every pharma manufacturer must achieve to bring new therapies to patients. The challenge lies in how to reach them.
Successfully navigating scale-up challenges in suppository drug products demands proactive regulatory planning, robust quality control approaches and cross-functional collaboration during technology transfer.
The U.S. government is currently investigating an ongoing antidumping and countervailing duty action looking into hard empty capsules from major trading partners.
More than an ambition or just another formulation strategy, patient-centric drug design is the future of pharma. As emerging technologies make gathering and implementing user feedback simpler than ever, historical barriers to progress are falling away.